{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:48:58Z","timestamp":1790938138557,"version":"4.1.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022805","name":"Dieter Morszeck Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022805","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01761-8","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:01:59Z","timestamp":1768348919000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma"],"prefix":"10.1186","volume":"19","author":[{"given":"Leon D.","family":"Kaulen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Karschnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Doubrovinskaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy S.","family":"Abramson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob D.","family":"Soumerai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Martinez-Lage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Erika","family":"Haydu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh M.","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirayu","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan D.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areej","family":"El-Jawahri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephraim P.","family":"Hochberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Connor","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Wick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela V.","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frigault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorg","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"issue":"11","key":"1761_CR1","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1182\/blood.2019001694","volume":"134","author":"MJ Frigault","year":"2019","unstructured":"Frigault MJ, Dietrich J, Martinez-Lage M, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019;134(11):860\u20136.","journal-title":"Blood"},{"issue":"15","key":"1761_CR2","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1182\/blood.2021014738","volume":"139","author":"MJ Frigault","year":"2022","unstructured":"Frigault MJ, Dietrich J, Gallagher K, et al. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1\/2 clinical trial. Blood. 2022;139(15):2306\u201315.","journal-title":"Blood"},{"issue":"1","key":"1761_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01508-3","volume":"16","author":"N Epperla","year":"2023","unstructured":"Epperla N, Feng L, Shah NN, et al. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study. J Hematol Oncol. 2023;16(1):111.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"1761_CR4","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1182\/blood.2021012932","volume":"139","author":"M Alcantara","year":"2022","unstructured":"Alcantara M, Houillier C, Blonski M, et al. CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network. Blood. 2022;139(5):792\u20136.","journal-title":"Blood"},{"issue":"3","key":"1761_CR5","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/bjh.19569","volume":"205","author":"N Epperla","year":"2024","unstructured":"Epperla N, Hashmi H, Ahn KW, et al. Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: a CIBMTR analysis. Br J Haematol. 2024;205(3):1202\u20137.","journal-title":"Br J Haematol"},{"issue":"22","key":"1761_CR6","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","volume":"23","author":"LE Abrey","year":"2005","unstructured":"Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034\u201343.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1761_CR7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"1761_CR8","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1182\/blood.2025028964","volume":"146","author":"LD Kaulen","year":"2025","unstructured":"Kaulen LD, Martinez-Lage M, Abramson JS, et al. Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy. Blood. 2025. https:\/\/doi.org\/10.1182\/blood.2025028964","journal-title":"Blood"},{"issue":"11","key":"1761_CR9","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1093\/neuonc\/noae115","volume":"26","author":"KR Tringale","year":"2024","unstructured":"Tringale KR, Scordo M, Yahalom J, et al. Outcomes and relapse patterns in primary central nervous system lymphoma: longitudinal analysis of 559 patients diagnosed from 1983 to 2020. Neuro Oncol. 2024;26(11):2061\u201373.","journal-title":"Neuro Oncol"},{"issue":"4","key":"1761_CR10","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/neuonc\/noae251","volume":"27","author":"L Hai","year":"2025","unstructured":"Hai L, Friedel D, Hinz F, et al. Distinct epigenetic and transcriptional profiles of Epstein-Barr virus-positive and negative primary CNS lymphomas. Neuro Oncol. 2025;27(4):979\u201392.","journal-title":"Neuro Oncol"},{"issue":"24","key":"1761_CR11","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1182\/blood.2022016945","volume":"140","author":"R Di Blasi","year":"2022","unstructured":"Di Blasi R, Le Gouill S, Bachy E, et al. Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis. Blood. 2022;140(24):2584\u201393.","journal-title":"Blood"},{"issue":"4","key":"1761_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1115940","volume":"5","author":"P Ot\u00e1hal","year":"2016","unstructured":"Ot\u00e1hal P, Pr\u016fkov\u00e1 D, Kr\u00e1l V, et al. Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells. Oncoimmunology. 2016;5(4):e1115940.","journal-title":"Oncoimmunology"},{"key":"1761_CR13","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1182\/blood-2018-99-112572","volume":"132","author":"AM Li","year":"2018","unstructured":"Li AM, Hucks GE, Dinofia AM, et al. Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia. Blood. 2018;132:556.","journal-title":"Blood"},{"issue":"7","key":"1761_CR14","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1002\/ajh.27316","volume":"99","author":"S Choquet","year":"2024","unstructured":"Choquet S, Soussain C, Azar N, et al. CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: real-life results of the LOC network. Am J Hematol. 2024;99(7):1240\u20139.","journal-title":"Am J Hematol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01761-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01761-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01761-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:01:59Z","timestamp":1768348919000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-025-01761-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1761"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01761-8","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board of the Massachusetts General Hospital approved the present study and waived informed consent given its retrospective nature.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Dr. Leon D. Kaulen reports consultiung fees from ONO Pharmaceutical. Dr. P. C. Johnson reports consulting fees from Abbvie, AstraZeneca, ADC Therapeutics, Bristol Myers Squibb, Kite, Novartin, Seagen, and research support from Incyte, AstraZeneca, Novartis and Leuko Labs. Dr. J. Soumerai reports consulting fees from AstraZeneca, Bristol Myers Squibb, Genentech\/Roche, and LOXO@Lilly, research support for investigator-initiated trials paid to the institution from Adaptive Biotechnologies, BeiGene, BostonGene, Genentech\/Roche, GlaxoSmithKline, Moderna, Takeda, and TG Therapeutics. Dr. J. Erika Haydu reports consulting fees and research funding paid to the institution from Genmab. Dr. W. Wick reports consulting fees and participation in advisory boards from Enterome, GSK, Roche and Servier. Dr. M. V. Maus is an inventor on patents related to adoptive cell therapies, held by Massachusetts General Hospital (some licensed to Promab and Luminary) and University of Pennsylvania (some licensed to Novartis). M.V.M receives Grant\/Research support from: Kite Pharma, Moderna. M.V.M has served as a consultant for multiple companies involved in cell therapies. M.V.M holds Equity in 2SeventyBio, A2Bio, Affyimmune, BendBio, Cargo, GBM new co, Model T bio. M.V.M serves on the Board of Directors for 2Seventy Bio. Dr. M. J. Frigault reports consulting fees and research support from Bristol Myers Squibb, Arcellx, Kite\/Gilead, Jnj\/Legend, Novartis, and Cytoagents. Dr. J. Dietrich reports consulting fees from Novartis, Janssen, and Johnson & Johnson, and royalties from Wolters Kluwer. All remaining authors have declared no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}